Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for halo
22.10
-0.40 (-1.78%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.63 - 22.47
52 week 7.51 - 23.16
Open 22.44
Vol / Avg. 992,983.00/1.61M
Mkt cap 2.86B
P/E     -
Div/yield     -
EPS -0.46
Shares 127.26M
Beta 0.92
Inst. own 75%
Aug 10, 2015
Q2 2015 Halozyme Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Halozyme Therapeutics Inc at JMP Securities Life Sciences Conference
May 18, 2015
Halozyme Therapeutics Inc at UBS Global Healthcare Conference
May 14, 2015
Halozyme Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Halozyme Therapeutics Inc Earnings Call
May 11, 2015
Q1 2015 Halozyme Therapeutics Inc Earnings Release
May 6, 2015
Halozyme Therapeutics Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -80.94% -90.76%
Operating margin -74.53% -83.68%
EBITD margin - -81.34%
Return on average assets -37.28% -51.07%
Return on average equity -153.61% -640.16%
Employees 153 -
CDP Score - -

Address

11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Officers and directors

Kathryn E. Falberg Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Helen I. Torley President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Laurie Stelzer Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 56
Bio & Compensation  - Reuters
Athena Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 42
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth J. Kelley Independent Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal J. Kirk Independent Director
Age: 61
Bio & Compensation  - Reuters
Connie L. Matsui Independent Director
Age: 61
Bio & Compensation  - Reuters
Matthew L. Posard Independent Director
Age: 47
Bio & Compensation  - Reuters